详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more

63| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China. [2]Public Service Platform of Tumor Organoids Technology, Hunan Gynecological Tumor Clinical Research Center, Changsha, Hunan, China. [3]Department of Gynecological Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China. [4]Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. [5]Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China. [6]Institute of Clinical Pharmacology, Engineering Research Center for applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha, Hunan, China.

出处：

DOI：

ISSN：

关键词： ovarian cancer targeted medication immunomodulatory drug resistance PARP inhibitors anti-angiogenic drugs

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 2 区药学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区药学

JCR分区：

出版当年[2021]版：

Q1 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY

影响因子： 4.4 最新[2023版] 5 最新五年平均 5.988 出版当年[2021版] 6.455 出版当年五年平均 5.811 出版前一年[2020版] 5.6 出版后一年[2022版]

第一作者：

第一作者单位： [1]Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China. [2]Public Service Platform of Tumor Organoids Technology, Hunan Gynecological Tumor Clinical Research Center, Changsha, Hunan, China.

共同第一作者：

通讯作者：

通讯机构： [1]Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China. [2]Public Service Platform of Tumor Organoids Technology, Hunan Gynecological Tumor Clinical Research Center, Changsha, Hunan, China. [5]Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China. [6]Institute of Clinical Pharmacology, Engineering Research Center for applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha, Hunan, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer [2]Bepotastine sensitizes ovarian cancer to PARP inhibitors through suppressing NF-κB-triggered SASP in cancer-associated fibroblasts [3]抗血管药物治疗Ⅲ/Ⅳ期和复发性卵巢癌疗效的荟萃分析 [4]Advances and perspectives of PARP inhibitors [5]Cytoplasmic p21 is responsible for paclitaxel resistance in ovarian cancer A2780 cells [6]Silencing Wnt2B by siRNA Interference Inhibits Metastasis and Enhances Chemotherapy Sensitivity in Ovarian Cancer [7]Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review) [8]Cytoplasmic p21 is responsible for paclitaxel resistance in ovarian cancer A2780 cells [9]Systems approach to rational combination therapy: PARP inhibitors [10]PARP inhibitors in gastric cancer: beacon of hope